Your institution may have access to this item. Find your institution then sign in to continue.

Title: A multicentre, double-blind, placebo-controlled, randomized, parallel comparison, phase 3 trial to evaluate the efficacy and safety of pioglitazone add-on therapy in type 2 diabetic patients treated with metformin and dapagliflozin.
Authors: Lim, Soo; Lee, Seung-Hwan; Min, Kyung-Wan; Lee, Chang Beom; Kim, Sang Yong; Yoo, Hye Jin; Kim, Nan Hee; Kim, Jae Hyeon; Oh, Seungjoon; Won, Jong Chul; Kwon, Hyuk Sang; Kim, Mi Kyung; Park, Jung Hwan; Jeong, In-Kyung; Kim, Sungrae
Abstract: To investigate the efficacy and safety of pioglitazone compared to placebo when added to metformin plus dapagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, for patients with type 2 diabetes mellitus (T2DM).
Publication: Diabetes, obesity & metabolism, 2024, Vol 26, Issue 6, p2188
ISSN: 1463-1326
Publication type: Journal Article
DOI: 10.1111/dom.15526

We found a match

A multicentre, double-blind, placebo-controlled, randomized, parallel comparison, phase 3 trial to evaluate the efficacy and safety of pioglitazone add-on therapy in type 2 diabetic patients treated with metformin and dapagliflozin.